Business Segments · R&D
Business Segments — R&D
Amgen Business Segments — R&D decreased by 9.5% to $1.72B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.7%, from $1.49B to $1.72B.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2024
Last reportedQ1 2026
How to read this metric
Higher spending is necessary for long-term growth, but excessive spending without clinical success can hurt short-term profitability.
Detailed definition
Captures the investment in discovery, clinical trials, and regulatory processes required to bring new therapeutic candid...
Peer comparison
Standard 'R&D' expense reported by all pharmaceutical and biotech companies.
Metric ID:
amgn_segment_reportable_segment_research_and_developmentHistorical Data
7 periods
| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $1.34B | $1.45B | $1.45B | $1.49B | $1.74B | $1.90B | $1.72B |
| QoQ Change | — | +7.7% | +0.2% | +2.5% | +17.4% | +8.9% | -9.5% |
| YoY Change | — | — | — | +10.6% | +20.5% | +31.0% | +15.7% |
Range$1.34B – $1.90B
CAGR+17.9%
Avg YoY Growth+19.5%
Median YoY Growth+18.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's business segments — r&d?
- Amgen (AMGN) reported business segments — r&d of $1.72B in Q1 2026.
- How has Amgen's business segments — r&d changed year-over-year?
- Amgen's business segments — r&d increased by 15.7% year-over-year, from $1.49B to $1.72B.
- What does business segments — r&d mean?
- The amount spent on developing new drugs and improving existing therapies.